Compare GSK plc (GSK) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? GSK plc trades at $50.37 (market cap $101.13B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.56. The key difference: GSK plc pays a 3.61% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and GSK plc is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| GSK | VCIT | |
|---|---|---|
Market Cap | $101.13B | — |
Sector | Health | Fixed Income |
52-Week High | $61.18 | $84.82 |
52-Week Low | $38.96 | $81.07 |
Enterprise Value | $121.57B | — |
Dividend Yield | 3.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $81.20 with a slight 0.16% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators are neutral. The fund maintains consistent monthly dividend distributions, with recent payouts around $0.33-$0.34. News highlights VCIT's competitive 0.03% expense ratio and approximately 5% yield compared to peers like iShares corporate bond ETFs, emphasizing its cost efficiency for income-focused investors.
The outlook for VCIT is mixed, offering attractive income through corporate bond exposure but facing interest rate sensitivity. Opportunities include high relative yield and low fees, while risks involve corporate credit deterioration and Fed policy shifts. Investors should weigh yield advantages against potential volatility from economic changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
